miR-378a-3p exerts tumor suppressive function on the tumorigenesis of esophageal squamous cell carcinoma by targeting Rab10

被引:40
作者
Ding, Naixin [1 ]
Sun, Xiujin [1 ]
Wang, Tingting [1 ]
Huang, Lei [1 ]
Wen, Jing [1 ]
Zhou, Yiqin [1 ]
机构
[1] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Radiotherapy,Jiangsu Canc Hosp, 42 Baiziting Rd, Nanjing 210009, Jiangsu, Peoples R China
关键词
microRNA-378a-3p; proliferation; migration; invasion; esophageal squamous cell carcinoma; Rab10; MICRORNA SIGNATURES; BREAST-CANCER; EXPRESSION; FIBROSIS; GTPASES;
D O I
10.3892/ijmm.2018.3639
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Esophageal squamous cell carcinoma (ESCC) is a life-threatening cancer with increasing incidence worldwide. MicroRNAs (miRs) have been reported to be involved in the progression of various types of cancer. In previous studies, the expression of miR-378a-3p was shown to be reduced in ESCC tissues. However, the mechanism underlying the effect of miR-378a-3p in ESCC remains to be elucidated. By employing a reverse transcription-quantitative polymerase chain reaction, miR-378a-3p expression was tested in ESCC tissues and cell lines. In addition, the effects of miR-378a-3p on cell viability, proliferation, apoptosis, migration and invasion were studied using an MTT assay, an EdU assay, flow cytometry analysis, wound healing analysis and a Transwell assay. In the present study, the level of miR-378a-3p was significantly downregulated in ESCC clinical tissues and cell lines (EC109 and KYSE150). In addition, the overexpression of miR-378a-3p suppressed the viability, proliferation, migration and invasion of the ESCC cells. The upregulated expression of miR-378a-3p also increased the expression levels of B-cell lymphoma 2-associated X protein and caspase-3, and decreased the expression levels of matrix metalloproteinase (MMP)-2 and MMP-9, which attenuated ESCC tumorigenesis. Furthermore, Rab10 was confirmed to be a direct target gene of miR-378a-3p, and was negatively affected by miR-378a-3p. The silencing of Rab10 revealed antitumor effects in ESCC cell lines, and the expression of miR-378a-3p was negatively correlated with that of Rab10 in ESCC. Collectively, miR-378a-3p may act as a tumor-suppressor in ESCC cells through negatively regulating Rab10.
引用
收藏
页码:381 / 391
页数:11
相关论文
共 32 条
[1]  
Arias Sosa Luis Alejandro, 2017, Rev. gastroenterol. Perú, V37, P65
[2]   Global incidence of oesophageal cancer by histological subtype in 2012 [J].
Arnold, Melina ;
Soerjomataram, Isabelle ;
Ferlay, Jacques ;
Forman, David .
GUT, 2015, 64 (03) :381-387
[3]   Rab10 associates with primary cilia and the exocyst complex in renal epithelial cells [J].
Babbey, Clifford M. ;
Bacallao, Robert L. ;
Dunn, Kenneth W. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2010, 299 (03) :F495-F506
[4]   The Rab protein family: Genetic mapping of six Rab genes in the mouse [J].
Barbosa, MDFS ;
Johnson, SA ;
Achey, K ;
Gutierrez, MJ ;
Wakeland, EK ;
Zerial, M ;
Kingsmore, SF .
GENOMICS, 1995, 30 (03) :439-444
[5]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[6]   Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer [J].
Chen, Yi ;
Luo, Donglin ;
Tian, Wuguo ;
Li, Zhirong ;
Zhang, Xiaohua .
ONCOLOGY REPORTS, 2017, 37 (06) :3581-3589
[7]   Causes and consequences of microRNA dysregulation in cancer [J].
Croce, Carlo M. .
NATURE REVIEWS GENETICS, 2009, 10 (10) :704-714
[8]   miR-378☆ Mediates Metabolic Shift in Breast Cancer Cells via the PGC-1β/ERRγ Transcriptional Pathway [J].
Eichner, Lillian J. ;
Perry, Marie-Claude ;
Dufour, Catherine R. ;
Bertos, Nicholas ;
Park, Morag ;
St-Pierre, Julie ;
Giguere, Vincent .
CELL METABOLISM, 2010, 12 (04) :352-361
[9]   Medical progress - Esophageal cancer [J].
Enzinger, PC ;
Mayer, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23) :2241-2252
[10]   Oncomirs - microRNAs with a role in cancer [J].
Esquela-Kerscher, A ;
Slack, FJ .
NATURE REVIEWS CANCER, 2006, 6 (04) :259-269